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Demineralized bone matrix (DBM) is one of the most widely used bone graft materials in
dentistry. However, the ability of DBM to reliably and predictably induce bone regeneration
has always been a cause for concern. The quality of DBM varies greatly depending
on several donor dependent factors and also manufacturing techniques. In order to
standardize the quality and to enable reliable and predictable bone regeneration, we
have generated a biomimetically-enhanced version of DBM (BE-DBM) using clinical
grade commercial DBM as a control. We have generated the BE-DBM by incorporating
a cell-derived pro-osteogenic extracellular matrix (ECM) within clinical grade DBM. In
the present study, we have characterized the BE-DBM and evaluated its ability to
induce osteogenic differentiation of human marrow derived stromal cells (HMSCs) with
respect to clinical grade commercial DBM. Our results indicate that the BE-DBM contains
significantly more pro-osteogenic factors than DBM and enhances HMSC differentiation
and mineralized matrix formation in vitro and in vivo. Based on our results, we envision
that the BE-DBM has the potential to replace DBM as the bone graft material of choice.
Keywords: demineralized bone matrix, biomimetic materials, mesenchymal stem cells, bone regeneration and
repair, extracellular matrix
INTRODUCTION
Bone is the second most transplanted organ in the human body (Marino and Ziran, 2010). Bone
grafting is used in several aspects of medicine ranging from placement of dental implants and spinal
fusions to regenerating lost bone resulting from trauma or congenital anomalies. With respect to
children, over 75% of birth defects are craniofacial anomalies (such as cleft palate) that require bone
reconstruction procedures (Zuk, 2008). Finally, with themany wars around the globe, the incidence
of injuries requiring bone reconstruction is at an all time high.
Over the past decade several natural and synthetic biomaterials have been developed to aid bone
regeneration (George and Ravindran, 2010). However, they have not been able to replace currently
used bone graft materials successfully. On the other hand, the focus of current research has shifted
away from improving the performance of existing clinical materials. The most immediate clinical
need lies in the generation of products that improve the performance of existing materials or
modified versions of existing clinical materials with improved performance. The focus of this study
is the generation of a modified bone graft material with superior osteoinductive properties.
The gold standard for bone regenerative procedures is autografts. In situations that require
significant quantity of bone to be regenerated, donor site morbidity becomes an issue with
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autografts. Under these circumstances, bone graft materials such
as allograft bone are used. DBM is a commonly used allograft
bone material. It is most commonly used in appendicular, axial
and craniofacial bone regenerative applications (Gruskin et al.,
2012). However, The quality and effectiveness of commercial
DBM varies with processing techniques and several donor
dependent factors (Zhang et al., 1997; Schwartz et al., 1998;
Lohmann et al., 2001; Traianedes et al., 2004). As a result,
bone regeneration and augmentation procedures do not have
predictable outcomes. Additionally, the osteoinductive and
osteogenic capacity of allograft DBM is significantly lesser than
autografts (Marino and Ziran, 2010).
Very few medical products have as much variability in
composition and performance as commercially available clinical
grade DBM. Several inconsistencies have been reported with
respect to DBM: The presence of osteoinductive growth factors
(such as BMPs) varies significantly between batches of DBM and
even amongst samples from the same batch (Bae et al., 2006,
2010). DBM from female donors has been shown to contain
higher quantities of BMPs (Pietrzak et al., 2006). DBM shows
variability in performance depending on donor age (Schwartz
et al., 1998) and finally revascularization of DBM and allograft
bone is poor (Delloye et al., 2007). Recently, several approaches
have been studied to enhance the effectiveness of DBM such as
remineralization (Soicher et al., 2013; Horváthy et al., 2015)and
use of platelet rich plasma (Han et al., 2009) with limited
and varied results. DBM in combination with bone marrow
aspirates has been used to treat bone cysts effectively (Park
et al., 2008; Di Bella et al., 2010), but it is not as effective when
used for fracture healing and large quantity bone regenerative
applications (Drosos et al., 2015).
Clinically, in order to augment bone regeneration,
recombinant BMP2 is used clinically. Although it is very
potent, dosage issues and ectopic effects are major problems
facing BMP2 usage. Many complications have been reported
recently causing serious safety concerns among clinicians
(Thibault et al., 2010; Zara et al., 2011).
We have attempted to solve the inherent problems associated
with DBM by generating a biomimetically-modified version of
clinical grade DBM. We have achieved this by incorporating
the native extracellular matrix (ECM) of differentiating
mesenchymal stem cells (MSCs) within it. We chose MSCs as the
source cell for creating the ECM, as the resulting matrix would be
a combination of MSC matrix and that of MSCs differentiating
into osteoblasts. This can provide an ideal environment for
patient specificMSCs. The other alternative would be osteoblasts.
However, osteoblasts have limited proliferative ability and hence
would not be able to populate the DBM as effectively as
MSCs. We have published previously on the standardization
of conditions and advantages of using biomimetic scaffolds for
tissue regeneration (Ravindran et al., 2012, 2014b). We have used
these techniques to develop a modified clinical product with
enhanced performance. The aim of this study was to evaluate
the ability of our biomimetically enhanced DBM (BE-DBM) in
comparison with commercial DBM using in vitro and in vivo
experimental models to analyze if the BE-DBM depicts improved
stem cell attachment, proliferation and differentiation abilities.
MATERIALS AND METHODS
Cell Culture
Human marrow stromal cells were used in this study (HMSCs).
These primary cells were obtained from NIH-funded center
for research resources, Tulane Center for the preparation and
distribution of adult stem cells. The cells are representative of
marrow stromal cells from five donors between the age groups
of 19 and 29 consisting of both male and female donors (Sekiya
et al., 2002). We have published previously using these cells and
they have been verified for multipotetncy (Ravindran et al., 2012,
2014a, 2015). The cells were cultured in αMEM basal media
(Gibco) with 20% FBS (Gibco), 1% L-glutamine (Gibco) and 1%
antibiotic-antimycotic solution (Gibco).
Generation of BE-DBM
BE-DBM was generated using clinical grade commercial DBM.
Two different types of DBM were used to generate BE-DBM. For
the in vitro experiments, we used DBM granules alone. For the
in vivo experiments, we used DBM granules containing cortical
bone chips to serve as internal control for mineralized matrix.
For each of the two types of DBM, we used three vials to generate
the BE-DBM. Once the BE-DBM was prepared, they were stored
as lyophilized samples until required for experimental use.
BMSCs were seeded on to the DBM at a concentration
of 1 million cells per 250mg of DBM granules and cultured
in standard BMSC culture media for a period of 24 h. After
this, the cells were cultured for 2 weeks in osteogenic culture
media (growth media containing100µg/ml ascorbic acid, 10mM
β-glycerophosphate and 10mM dexamethasone). This was
performed to induce osteogenic differentiation of the BMSCs and
to facilitate the generation of a pro-osteogenic matrix. After 2
weeks, the DBM granules containing BMSCs were decellularized
using our published protocol (Ravindran et al., 2012, 2014a,b).
Briefly, the samples were incubated for 1 h at 37◦C in TBS
containing 0.5% triton x-100. After this, the cells were lysed
using 25mM ammonium hydroxide solution. They were then
washed extensively in TBS followed by one wash inHBSS. Finally,
DNAse digestion was performed and the samples were washed
in double deionized water extensively, lyophilized and stored.
Decellularization was verified by immunostaining for tubulin and
DAPI nuclear staining.
Proliferation Experiment
Twenty thousand HMSCs were seeded on to equal amounts of
DBM and BE-DBM in quadruplicates. Eight hours post seeding,
the unattached cells were removed by aspiration and the samples
were washed using three exchanges of fresh media to ensure
complete removal of all unattached cells. Twenty-four hours post
seeding, the number of live cells was quantitatively measured
using an MTT cell titer assay (Promega). The number of cells
present at various time points up to 1 week was also measured
to obtain the proliferation rate.
Electron Microscopy
Electron microscopic evaluation was performed on DBM and
BE-DBM in their natural state as well as when subjected to
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in vitro mineralization. To generate mineralized DBM and BE-
DBM, in vitro mineralization experiment was performed as
per previously published protocols (Ravindran et al., 2014b).
Electron microscopic evaluation of the samples was performed
after coating the samples with platinum and palladium using
Hitachi S3000 electron microscope. Energy dispersive X-ray
(EDX) analysis in variable pressure mode was performed to
obtain elemental information on the mineralized samples and
also to obtain ratios of calcium to phosphorus in the samples. For
all EDX analyses, the samples were not coated.
In Vitro Differentiation of HMSCs
500,000 HMSCs were seeded on to 50mg of DBM or BE-
DBM and cultured in standard growth media for 2 weeks in
quadruplicates. After 2 weeks, the RNA was isolated from both
sets of samples. After first strand synthesis (BioRad first strand
synthesis kit), quantitative real time PCR (qPCR) was performed
using gene specific primers. Table 1 lists the primer sequences
used in this study. All expression data were normalized to
housekeeping genes GAPDH and B2M.
In Vivo Implantation
All experiments were performed in accordance with approved
animal care protocols (Assurance No: A3460-01). 500,000
HMSCs were seeded on to 50mg of DBM or BE-DBM
encapsulated in collagen sponges (Zimmer collagen tape) and
implanted subcutaneously on the back of 2-month-old athymic
male nude mice for a period of 2 weeks. Experiments were
performed in triplicate. We had two groups one with commercial
DBM and the other with BE-DBM. Two implants were placed on
the back of each mouse. On one side, we placed the DBM implant
and the other side contained the BE-DBM implant. Therefore, a
total of three mice were used for this study. After 2 weeks, the
samples were extracted, fixed in 4% neutral buffered formalin,
paraffin embedded and sectioned.
Histology and Immunohistochemistry
Hematoxylin and eosin (H&E) staining and alizarin red staining
was performed as per previously published protocols (Ravindran
et al., 2014a). Expression of proteins in the explant sections
as well as DBM and BE-DBM sections were performed either
using peroxidase conjugated secondary antibodies (Vector
Laboratories DAB kit) or using secondary antibodies conjugated
to fluorescent probes. The following primary antibodies were
used: rabbit polyclonal anti fibronectin antibody (1/250, abcam),
mouse monoclonal anti tubulin antibody (1/1000, Sigma),
mouse monoclonal anti bone morphogenetic protein 2 (BMP2)
antibody (1/100, abcam), rabbit polyclonal anti transforming
growth factor β1 (TGFβ) antibody (1/100, abcam), mouse
monoclonal anti phosphorylated serine (pSer) antibody (1/100,
Santa Cruz biotechnology), mouse monoclonal anti DMP-
1 antibody (1/1000, a gift from Dr. Chunlin Qin, Baylor
College of Dentistry), mouse monoclonal anti osteocalcin
antibody (1/100, abcam), mouse monoclonal anti runt-related
transcription factor x2 (RUNX2) antibody (1/100, abcam), mouse
monoclonal anti von Willebrand factor antibody (1/100, Santa
Cruz biotechnology), rabbit polyclonal anti VEGF antibody
(1/100, abcam).
Fluorescent microscopy was performed using a Zeiss LSM
710 laser scanning confocal microscope or a BioRad Zoe
fluorescent microscope. For all comparative samples, the imaging
parameters were maintained constant. For peroxidase stained
sections, microscopy was performed using a Zeiss Axio Observer
D1 microscope or an EVOS XL Core microscope (Life
Technologies).
Quantitation of Proteins in DBM and
BE-DBM
ELISA was used to quantitate the amount of a few important pro-
osteogenic proteins in the DBM and BE-DBM. Equal amounts
of both materials (10mg) were placed in 96 well plates in
quadruplicates. The material was blocked with 5% BSA for 1 h
and incubated with the appropriate primary antibody overnight
at 4◦C. The samples were then washed four times in PBS and
incubated with a biotinylated secondary antibody (1/250, Vector
Laboratories) and then subsequently washed four times with
PBS and incubated with peroxidase conjugated avidin (Vector
Laboratories) for 1 h at room temperature. Finally, the samples
were incubated with an ELISA substrate (Turbo TMB ELISA
substrate, Thermo Scientific) for 5min at room temperature.
The reaction was stopped by the addition of 1M sulfuric acid.
The solution was then transferred to empty 96 well plate wells
and absorbance at 490 nm was recorded. The following primary
TABLE 1 | qPCR primer sequences.
Gene Forward Reverse
FGF2 5′-AGA AGA GCG ACC CTC ACA TCA-3′ 5′-CGG TTA GCA CAC ACT CCT TTG-3′
GDF10 5′-AGA TCG TTC GTC CAT CCA ACC-3′ 5′-GGG AGT TCA TCT TAT CGG GAA CA-3′
PHEX 5′-GAG GCA CTC GAA TTG CCC T-3′ 5′-ACT CCT GTT TAG CTT GGA GAC TT-3′
OCN 5′-AGC CCA TTA GTG CTT GTA AAG G-3′ 5′-CCC TCC TGC TTG GAC ACA AAG-3′
VEGFA 5′-AGG GCA GAA TCA TCA CGA AGT-3′ 5′-AGG GTC TCG ATT GGA TGG CA-3′
GAPDH 5′-CAG GGC TGC TTT TAA CTC TGG-3′ 5′-TGG GTG GAA TCA TAT TGG AAC A-3′
B2M 5′-GAG GCT ATC CAG CGT ACT CCA-3′ 5′-CGG CAG GCA TAC TCA TCT TTT-3′
DMP1 5′-CTC CGA GTT GGA CGA TGA GG-3′ 5′-TCA TGC CTG CAC TGT TCA TTC-3′
Table showing the forward and reverse primer sequences for the genes used in the real time PCR analyses.
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antibodies were used: rabbit polyclonal anti fibronectin antibody
(1/500), mouse monoclonal anti BMP2 antibody (1/250), rabbit
polyclonal anti VEGF antibody (1/250), mouse monoclonal anti
phosphorylated serine, threonine, and tyrosine antibody (1/1000,
abcam).
Statistical Analysis
Student’s t-test was performed for the indicated experiments
to verify statistical significance. A P < 0.05 (95% confidence
interval) was considered as statistically significant.
RESULTS
Characterization of BE-DBM for Enhanced
Presence of Pro-osteogenic Proteins
DBM and BE-DBM sections were immunostained for the
presence of several ECM proteins and growth factors that play
an important role in osteogenesis and osteogenic differentiation
of MSCs. Figure 1 shows representative images of 3D confocal
microscopy. Results presented in Figure 1 show that the BE-
DBM contains more pro-osteogenic proteins when compared to
the commercially available DBM. The BE-DBM was generated
using the DBM from the same container and hence, the results
are directly comparable. In the results presented in Figure 1,
tubulin was used as a negative control to show the absence
of intracellular proteins (Figures 1B,B1). DAPI staining was
performed to show the absence of cellular DNA (Figures 1C,C1).
Rabbit and mouse secondary antibody controls were performed
to show absence of non-specific staining (Figures 1D,D1).
The results presented in Figure 1 show that the BE-
DBM contains more structural proteins such as fibronectin
(Figure 1A vs. Figure 1A1), growth factors (Figures 1F,G
vs. Figures 1F2,G1), pro-angiogenic factors such as VEGF
(Figure 1E vs. Figure 1E1), phosphorylated proteins (Figure 1H
vs. Figure 1H1) proteases (Figure 1I vs. Figure 1I1), and
nucleating proteins (Figure 1J vs. Figure 1J1).
ELISA was used to quantify the increased presence of
fibronectin, BMP2, VEGF, and phosphorylated proteins. The
graph presented in Figure 1K shows a statistically significant
increase in the presence of these proteins within the BE-DBM
when compared to DBM.
Electron Microscopic Evaluation of DBM
and BE-DBM
The microstructure of DBM and BE-DBM was evaluated
using electron microscopy. Figure 2 represents results from
FIGURE 1 | ECM proteins in DBM and BE-DBM. Images compare the expression of representative ECM proteins in DBM (A–J) and BE-DBM (A1–J1). All images
except B,B1,C,C1,D,D1 (scale bar represents 20µm for these images) are 3D renderings of z-stack confocal images. Tubulin (B,B1) was used as a negative control
for absence of intracellular proteins and DAPI (C,C1) nuclear staining was used as negative control for absence of cellular DNA. Immunostaining was performed for
Fibronectin (A,A1), VEGF (E,E1), BMP2 (F,F1), TGFβ1 (G,G1), proteins containing phosphorylated serines (H,H1) matrix metalloproteinase 2 (MMP2, I,I1) and DMP1
(J,J1). Panel (K) is a graphical representation of the relative amounts of select ECM proteins in both DBM and BE-DBM (n = 4). The quantified proteins were:
Fibronectin (FIB), BMP2, VEGF, and phosphorylated proteins (P-ser/thr/tyr). Statistical significance was measured using student’s t-test. *Represents statistical
significance with P < 0.05 and #represents statistical significance with P < 0.1. Phosphorylated proteins were quantified using an antibody that recognizes
phosphorylated serine, threonine and tyrosine residues.
Frontiers in Physiology | www.frontiersin.org 4 October 2015 | Volume 6 | Article 292
Ravindran et al. Biomimetically enhanced DBM
FIGURE 2 | Electron microscopic evaluation of DBM and BE-DBM. Images are representative electron micrographs of DBM (A,B), DBM with HMSCs (A1,B1)
and BE-DBM (A2,B2). Panels (A,A1,A2) are low magnification images. Panels (B–B2) are higher magnification images showing the microstructure. The white arrows
in (A1,B1) point to the cells. White arrows in (A2,B2) point to ECM deposition in the BE-DBM samples. Note the absence of such structures in images (A,B).
FIGURE 3 | Attachment and proliferation of HMSCs in DBM and BE-DBM. (A) Represents 3D renderings of z-stack confocal images of HMSCs within DBM
and BE-DBM after 1 day and 1 week. These images provide qualitative proof that the BE-DBM promotes enhanced stem cell attachment and proliferation. The
color-coding in the renderings represents depth as indicated by the depth scale below. (B) Represents proliferation of HMSCs in the DBM (dotted lines) and BE-DBM
(solid lines) over 1 week. The data points represent mean of quadruplicates with standard deviation as error. The slope of the linear lines (dotted lines for DBM and
solid lines for BE-DBM) provides the rate of proliferation. HMSCs in the BE-DBM showed a 34.52% increase in proliferation rate. The boxed region in the graph
represents data obtained at day 1. A 34.07% (P < 0.01 by student’s t-test) increase in initial cell attachment was seen in BE-DBM with respect to DBM. The data at all
time points was statistically significant with P < 0.05. *above each point represents statistical significance.
this experiment. Figures 2A,B are images of commercial DBM.
Figures 2A1,B1 show the presence of HMSCs on the DBM
before decellularization is performed. Figures 2A2,B2 show
images of BE-DBM containing the cell-secreted ECM. Upon
comparing Figures 2A,B pertaining to DBM with Figure 2A2
and Figure 2B2 pertaining to BE-DBM it is possible to observe
increased presence of fibrillar structures within the BE-DBM
samples. The white arrows in Figure 2A2 and Figure 2B2
point to these structures. These structures represent the ECM
deposition within the DBM.
The BE-DBM Promotes Improved Stem
Cell Attachment and Proliferation
An MTT assay was used to quantitate proliferation of HMSCs
on DBM and BE-DBM. Results presented in Figure 3B show that
the BE-DBM promotes improved stem cell attachment (boxed
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FIGURE 4 | In vitro regulation of osteogenic genes. The graph represents fold change in gene regulation of key pro-osteogenic genes and growth factors in
BE-DBM with respect to control DBM. Data are represented as mean fold change obtained from quadruplicate experiments with standard deviation as error. Student’s
t-test used to obtain statistical significance with respect to control. *Represents significance of P < 0.05.
area representing the 1 day time point). A 34.07% (P < 0.01
by student’s t-test) increase in cellular attachment was observed
in the BE-DBM compared to DBM. Rate of proliferation was
obtained by calculating the slope of the lines representing
proliferation of the cells over a period of 1 week. The results
showed that the BE-DBM enhanced the rate of proliferation of
HMSCs by 34.52%.
Figure 3A shows representative images of HMSCs in DBM
and BE-DBM after 1 day and 7 days. The images show
qualitatively the increased presence of cells in the BE-DBM at
these time points.
The BE-DBM Promotes Improved
Osteogenic Differentiation of HMSCs in
Vitro
HMSCs were cultured under normal growth conditions in both
DBM and BE-DBM for 2 weeks. qPCR results presented in
Figure 4 show a statistically significant change in the expression
of several key pro-osteogenic proteins such as DMP1, phosphate
regulating endopeptidase homolog X (PHEX) and osteocalcin.
We also observed significant increase in the expression of
osteogenic growth factors such as growth and differentiation
factor 10 (GDF10) and FGF2 and pro angiogenic factor VEGF.
The BE-DBM Promotes Improved Matrix
Mineralization in Vitro
The ability of DBM and BE-DBM to promote nucleation of
calcium phosphate crystals was evaluated using an in vitro
nucleation experiment. Under these conditions, the DBM did
not nucleate a large amount of calcium phosphate crystals.
Results presented in Figures 5A,B show similar microstructure
to DBM that was not subjected to in vitro nucleation experiment
(Figures 2A,B). On the other hand, results presented in
Figures 5A1,B1 show the presence several structures resembling
nucleated calcium phosphate crystals. These images were
obtained from pt/pd-coated samples of mineralized DBM and
BE-DBM. In addition, imaging of mineralized DBM and BE-
DBM was performed on uncoated samples in variable pressure
mode. Results presented in Figure 5C show the presence of
a few calcium phosphate crystals in the DBM samples. The
bright areas in the image (white arrows) are calcium phosphate
deposits. The presence of calcium and phosphorus was verified
by EDX elemental analysis (Figure 5D). The ratio of calcium to
phosphorus in these deposits was 1.485 (S.D= 0.175, n = 8).
On the other hand, results presented in Figure 5C1 show
a very robust deposition of calcium phosphate throughout
the BE-DBM sample (white arrows). Presence of calcium and
phosphorus was verified using EDX analysis (Figure 5D1) and
the ratio of calcium to phosphorus was 1.645 (S.D = 0.106, n =
8). The difference in the Calcium to phosphorus ratio between the
two samples was statistically significant with a P-value of 0.033
using student’s t-test.
The BE-DBM Promotes Improved
Osteogenic Differentiation in Vivo
Gene expression data is not valuable if protein expression does
not follow in vivo. HMSCs were seeded on to DBM and BE-
DBM, wrapped in clinical grade collagen sponges and implanted
subcutaneously for 2 weeks in immunocompromised mice.
Results presented in Figure 6 show that the HMSCs in BE-DBM
Frontiers in Physiology | www.frontiersin.org 6 October 2015 | Volume 6 | Article 292
Ravindran et al. Biomimetically enhanced DBM
FIGURE 5 | In vitro calcium phosphate nucleation. Panels (A–C) are
representative electron micrographs of DBM samples subjected to in vitro
calcium phosphate nucleation. Panels (A1–C1) are electron micrographs of
BE-DBM samples subjected to in vitro nucleation. Note the increased
deposition on the BE-DBM samples. Panels (C,C1) were acquired using
samples that were not coated with pt/pd. White arrows in (C,C1) indicate
areas of calcium phosphate deposition. Panels (D,D1) are representative EDX
spectrums of DBM and BE-DBM samples respectively showing the presence
of calcium and phosphorus.
expressed higher amounts of osteocalcin, DMP1, BMP2, TGFβ1,
and RUNX2 when compared to those in commercial DBM.
The BE-DBM Promotes Enhanced
Mineralization and Vascularization in Vivo
The key to successful bone regeneration is collagen deposition
and matrix mineralization. The 2-week explant sections were
stained with H&E to observe general tissue architecture. Results
presented in Figures 7A,A1 show more robust eosin staining
in the BE-DBM sections compared to DBM sections indicating
a higher presence of collagen. Alizarin red staining was
performed to look for calcium deposition. Results presented
in Figures 7B,B1 show that the BE-DBM containing sections
showedmore robust staining with alizarin red indicating a higher
calcium deposition in the matrix.
The DBM that was used for generating the BE-DBM and
control DBM samples for in vivo experiments contained cortical
bone chips. The cortical bone chips served as an internal control
for collagen presence and calcium presence in natural bone. The
black arrows in Figures 7A,A1,B,B1 point to cortical bone chips.
Angiogenesis is vital for bone regeneration. Our results
indicate that the BE-DBM contains more VEGF compared to
commercially available DBM (Figures 1E,E1). We analyzed if
this translated to improved vascularization in vivo. The BE-
DBM sections showed a higher amount of von Willebrand factor
positive endothelial cells than the DBM sections (Figures 7C,C1)
indicating that the BE-DBM promoted migration of host
endothelial cells better than DBM. We quantified the von
Willebrand factor staining. Six images spanning three samples for
each group were used for this purpose. In the BE-DBM samples,
on an average 10.53% of the area in the images stained positive for
von Willebrand factor as opposed to 2.15% in the DBM samples.
Student’s t-test on the data showed a P-value of 0.0196 indicating
that the data was statistically significant.
Additionally, the DBM samples did not show any endothelial
cells within the samples. In certain areas, we were able to observe
endothelial cells in the periphery of the sample. However, these
may include some mouse connective tissue as well. We included
these areas as well in our calculation. The * in Figures 7C,C1
indicate cortical bone chips. When the H&E stained sections
were imaged using a confocal microscope, RBCs were observed
only in the BE-DBM sections indicating active blood flow
(Figures 7D,D1). This data corroborates well with the von
Willebrand factor staining of the samples that indicated that
there were no endothelial cells within the DBM samples. The
presence of RBCs were not scattered, but concentrated in the
shape of vessels (yellow arrows in Figure 7D) indicating that
they were not from random bleeding. Finally, no secondary
antibody non-specific staining was observed in our experiments
(Figures 7E,E1).
DISCUSSION
The ECM is a dynamic environment that dictates cellular
behavior and tissue functionality. We have published several
articles on the use of decellularized ECM as a biomimetic
biomaterial for tissue regeneration (Ravindran et al., 2012,
2014a,b). Decellularized biomimetic matrices have gained
prominence recently and have been evaluated for several tissue
engineering applications such as heart (Moroni and Mirabella,
2014), lung (Petersen et al., 2012; Calle et al., 2015), and cartilage
(Schwarz et al., 2012). The advantage of these matrices over
other biomaterials is that they can provide a tissue specific
environment. Several studies have shown the effectiveness and
safety of this process (Crapo et al., 2011). The limitation however,
is the maintenance of tissue integrity (Moroni and Mirabella,
2014). In the case of DBM this is not an issue as the starting
material itself is demineralized and decellularized bone particles.
In this study, we have characterized a biomimetically-
enhanced version of clinical DBM that has the potential
to significantly improve the quality of bone regenerative
procedures. Our results show that the BE-DBM contains
significantly more pro-osteogenic factors. One of the significant
observations was the increased presence of fibronectin.
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FIGURE 6 | Immunohistochemistry of DBM and BE-DBM in vivo explants. All images except secondary antibody controls (F,F1) are 3D renderings of z-stack
confocal images. Scale bar in (F,F1) represents 20µm. The 3D images represent expression of osteocalcin (OCN, A,A1), DMP1 (B,B1), TGFβ1 (C,C1), BMP2 (D,D1),
and RUNX2 (E,E1) in DBM (A–E) and BE-DBM (A1–E1) samples after 2 weeks of subcutaneous implantation with HMSCs in immunocompromised mice. Note the
marked increase in the expression levels of all the proteins in the BE-DBM.
FIGURE 7 | Histology of DBM and BE-DBM in vivo explants. (A,A1) Represent H&E stained sections of DBM and BE-DBM explants, respectively. The arrow in
(A) points to a cortical bone chip. (B,B1) Represent alizarin red stained sections from DBM and BE-DBM explants. (C,C1) Represent DBM and BE-DBM sections
immunohistochemically stained for von Willebrand factor. The arrows in (C1) point to positively stained endothelial cells in the BE-DBM section. *Symbols in (C,C1)
represent cortical bone chips. (D,D1) Represent 3D confocal images of red channel auto fluorescence from H&E stained DBM and BE-DBM sections. The yellow
arrows in (D1) point to RBCs. (E,E1) Represent mouse secondary antibody controls for the DBM and BE-DBM sections. Scale bar in all other images represents
20µm.
Fibronectin binds several growth factors (Goerges and Nugent,
2004; Zhu and Clark, 2014). Therefore, an increase in fibronectin
can result in increased sequestration of growth factors in vivo.
Apart from fibronectin, growth factors such as VEGF, BMP2, and
TGFβ1 were also observed in increased amounts in the BE-DBM
compared to DBM. The BE-DBM also contained significantly
higher amounts of phosphorylated proteins. Phosphorylated
proteins serve as the source for inorganic phosphorus during
hydroxyapatite nucleation. Therefore, the increased presence of
these proteins was an encouraging sign that the BE-DBM may
promote faster and better nucleation. Although the qualitative
and quantitative data provided in this study is not an exhaustive
list of proteins present in the matrix, they provide a good
overview to summarize that the BE-DBM that we have generated
contains significantly more pro-osteogenic proteins.
During bone regeneration, recruitment of MSCs to the
site is critical for new bone formation. Therefore, a bone
regenerative material should possess the ability to promote
stem cell attachment and proliferation. The BE-DBM promoted
improved stem cell attachment and proliferation compared to
DBM indicating its enhanced potential to recruit stem cells.
Additionally, the BE-DBM also promotes better osteogenic
differentiation of MSCs compared to DBM.
Our results indicated statistically significant regulation of key
pro-osteogenic genes. Our results indicated a significant increase
in the expression levels of PHEX, DMP1 and OC. PHEX and
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DMP1 are extremely important for mineralizedmatrix formation
and regulate FGF23 expression (Martin et al., 2011). PHEX is
an endopeptidase that acts upon the mineralization inhibitor
osteopontin to positively regulate mineralized matrix formation
(Zhu and Clark, 2014). DMP1 is a multi-functional pro-
osteogenic protein that possesses several intra and extracellular
roles ranging from control of MSC differentiation to serving as a
collagen binding protein that actively nucleates hydroxyapatite
(He et al., 2003; He and George, 2004; Ravindran et al., 2008;
Eapen et al., 2010). OC is one of the most abundant non-
collagenous proteins in bone. OC acts as an endocrine hormone
and plays a pivotal role in bone formation and increase in bone
mineral density (Lee et al., 2007). Apart from these key regulators
of bone formation, the BE-DBM also stimulated an increase in
the expression levels of the pro-angiogenic growth factor VEGF
and pro-osteogenic growth factors GDF10 (Kaihara et al., 2003;
Marsell and Einhorn, 2009) and FGF2 (Hong et al., 2010; Kigami
et al., 2013). These results indicated the enhanced potential of the
BE-DBM to induce MSC differentiation.
When subjected to in vitro nucleation experiments to
explore the calcium phosphate nucleating ability of the BE-
DBM compared to DBM, the BE-DBM showed a more robust
nucleating ability with calcium to phosphorus ratio similar to
that of hydroxyapatite found in bone. Collectively, our in vitro
experiments indicated that the BE-DBM is better than DBM
in promoting stem cell attachment, proliferation, differentiation
and hydroxyapatite nucleation.
When BE-DBM and DBM were compared in vivo in
a subcutaneous implantation model with HMSCs, the BE-
DBM promoted better collagen synthesis and formation of a
better-calcified matrix as evidenced by our histological data.
These observations are in line with our in vitro data that
indicated the ability of the BE-DBM to promote these events
better than DBM. Additionally, in line with the positive
regulation of pro-angiogenic factors in vitro, the BE-DBM
also promoted better migration of host endothelial cells and
vascularization when compared to commercial DBM. Finally,
fluorescence immunohistochemistry of the explant sections
revealed that the BE-DBM was able to promote better osteogenic
differentiation of MSCs by inducing higher levels of expression
of pro-osteogenic non-collagenous proteins such as OC and
DMP1, growth factors such as BMP2 and TGFβ1 (Yamamoto
et al., 2000; Ozkan et al., 2007) and important pro-osteogenic
transcription factors such as RUNX2 (Komori, 2008; Zhang
et al., 2009). These results indicated that the BE-DBM
accelerated osteogenic differentiation and matrix mineralization
in vivo.
Overall, the data presented in this manuscript shows that
the BE-DBM promotes better differentiation of HMSCs in vitro
and in vivo. However, further investigation using large animal
critical-size bone defect models is required to verify the improved
osteoinductive properties of BE-DBM. Our efforts at present
are focused on these models and if successful, this product can
bring about standardization to the quality and performance of
DBM that is critically lacking at present. DBM is widely used in
craniofacial bone regeneration, spinal fusion and in non-union
fracture healing in conjunction with autologous bone (Gruskin
et al., 2012). Based on our results, we predict that the BE-DBM
will enable faster regeneration of higher quality bone in these
applications.
This is the first report that shows that it is possible to generate
a biomimetic ECM incorporated DBM that has the potential
replace the existing material. The amount of ECM incorporated
within DBM to generate BE-DBM can be standardized by the
use of cell lines and by controlling the cell number, density and
culture conditions using a bioreactor. If these conditions are
standardized, it is feasible to scale up the production of BE-DBM
for commercial use.
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